Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036

TheFly reported connected June 10 that AKBA strengthened the intelligence spot extortion for its flagship therapy, Vafseo (vadadustat), aft receiving a caller patent listing successful the FDA's Orange Book and notification of eligibility for a five-year hold of a creation of substance patent. The additions heighten the company's existing patent portfolio, which present includes 14 Orange Book-listed patents covering Vafseo with extortion extending done 2036. These developments further enactment the company's efforts to support the semipermanent worth and commercialized imaginable of the therapy.

Earlier connected May 7, Akebia Therapeutics, Inc. (NASDAQ:AKBA) reported its first-quarter 2026 fiscal results, highlighting continued advancement for Vafseo and its kidney illness pipeline. Vafseo nett merchandise gross reached $15.8 cardinal during the quarter, portion the fig of patients utilizing the therapy accrued astir 60% compared with the extremity of the anterior quarter. The institution besides reported astir 1,025 prescribers, representing a 28% summation from Q4 2025. Total first-quarter gross was $53.5 million, compared with $57.3 cardinal successful the aforesaid play past year. AKBA continued advancing objective programs, including praliciguat successful FSGS and AKB-097 successful uncommon kidney diseases, portion maintaining currency resources of astir $162.6 cardinal arsenic of March 31, 2026.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is simply a biopharmaceutical institution focused connected processing and commercializing innovative therapies for patients with kidney disease.

While we admit the imaginable of AKBA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.